Trial Profile
ONO-4538 Multicenter, Open-label, Single-arm, Phase II Study in Advanced Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 19 Apr 2022 Status changed from active, no longer recruiting to completed.
- 30 Sep 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2021.
- 03 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jul 2017.